Should I buy or sell Organon & Co. stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OGN shares. View OGN analyst ratings or view top-rated stocks .

What is Organon & Co.'s stock price target for 2024?

5 Wall Street research analysts have issued twelve-month price targets for Organon & Co.'s stock. Their OGN share price targets range from $16.00 to $33.00. On average, they predict the company's share price to reach $23.33 in the next year. This suggests a possible upside of 110.4% from the stock's current price. View analysts price targets for OGN or view top-rated stocks among Wall Street analysts .

How have OGN shares performed in 2023?

Organon & Co.'s stock was trading at $27.93 at the beginning of 2023. Since then, OGN shares have decreased by 60.3% and is now trading at $11.09. View the best growth stocks for 2023 here .

Are investors shorting Organon & Co.?

Organon & Co. saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 14,620,000 shares, an increase of 36.3% from the October 31st total of 10,730,000 shares. Based on an average daily volume of 4,550,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 5.7% of the company's stock are short sold. View Organon & Co.'s Short Interest .

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024. View our OGN earnings forecast .

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) announced its earnings results on Thursday, November, 2nd. The company reported $0.78 EPS for the quarter, missing analysts' consensus estimates of $1.04 by $0.26. The firm had revenue of $1.52 billion for the quarter, compared to analysts' expectations of $1.59 billion. Organon & Co. had a net margin of 9.51% and a negative trailing twelve-month return on equity of 147.13%.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. declared a quarterly dividend on Thursday, November 2nd. Stockholders of record on Monday, November 13th will be given a dividend of $0.28 per share on Thursday, December 14th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 10.10%. The ex-dividend date is Friday, November 10th. Read our dividend analysis for OGN .

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 9.74%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 48.91%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 26.92% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for OGN .

What ETFs hold Organon & Co.'s stock?

ETFs with the largest weight of Organon & Co. (NYSE:OGN) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , Emerge EMPWR Sustainable Dividend Equity ETF (EMCA) , Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) , VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE) .

Who are Organon & Co.'s major shareholders?

Organon & Co.'s stock is owned by a variety of retail and institutional investors. Top institutional investors include Mawer Investment Management Ltd. (5.03%), Invesco Ltd. (4.01%), Massachusetts Financial Services Co. MA (3.63%), Lord Abbett & CO. LLC (1.97%), Sound Shore Management Inc CT (1.35%) and Morgan Stanley (1.19%). View institutional ownership trends .

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Organon & Co. Stock Price, News & Analysis (NYSE:OGN)

$11.09

-0.74 (-6.26%)

(As of 12/5/2023 ET)

Compare

Today's Range: $11.07
▼
$11.81
50-Day Range: $10.95
▼
$17.37
52-Week Range: $10.90
▼
$32.43

Volume: 4.58 million shs
Average Volume: 2.85 million shs
Market Capitalization: $2.83 billion

P/E Ratio: 4.84
Dividend Yield: 10.10%
Price Target: $23.33

Organon & Co. MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 110.4% Upside
$23.33 Price Target
Short Interest: Bearish
5.73% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.38
Upright™ Environmental Score
News Sentiment: -0.66
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 2.72%
From $4.05 to $4.16 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

57th out of 948 stocks

Pharmaceutical Preparations Industry

12th out of 421 stocks

3.3

Analyst's Opinion

Consensus Rating
Organon & Co. has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.33, Organon & Co. has a forecasted upside of 110.4% from its current price of $11.09.
Amount of Analyst Coverage
Organon & Co. has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.73% of the float of Organon & Co. has been sold short.
Short Interest Ratio / Days to Cover
Organon & Co. has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Organon & Co. has recently increased by 36.25%, indicating that investor sentiment is decreasing significantly.

3.3

Dividend Strength

Dividend Leadership
Organon & Co. is a leading dividend payer. It pays a dividend yield of 9.74%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Organon & Co. does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Organon & Co. is 48.91%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Organon & Co. will have a dividend payout ratio of 26.92% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.

3.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Organon & Co. has received a 38.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ezetimibe", "Contraceptive implants", "Losartan", "Montelukast", and "Contraceptives" products. See details.
Environmental Sustainability
The Environmental Impact score for Organon & Co. is -2.38.

1.3

News and Social Media Coverage

News Sentiment
Organon & Co. has a news sentiment score of -0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Organon & Co. this week, compared to 3 articles on an average week.
Search Interest
41 people have searched for OGN on MarketBeat in the last 30 days. This is an increase of 105% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Organon & Co. insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.17% of the stock of Organon & Co. is held by insiders.
Percentage Held by Institutions
77.08% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Organon & Co. are expected to grow by 2.72% in the coming year, from $4.05 to $4.16 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Organon & Co. is 4.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.88.
Price to Earnings Ratio vs. Sector
The P/E ratio of Organon & Co. is 4.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.20.
Price to Earnings Growth Ratio
Organon & Co. has a PEG Ratio of 0.39. PEG Ratios below 1 indicate that a company could be undervalued.

See Top Rated MarketRank™ Stocks Here

About Organon & Co. Stock (NYSE:OGN)

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OGN Stock News Headlines

November 30, 2023 | seekingalpha.com

Organon: It's Darkest Before The Dawn

November 29, 2023 | seekingalpha.com

Organon & Co (OGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)

December 6, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

November 22, 2023 | markets.businessinsider.com

Analyst Expectations for Organon's Future

November 21, 2023 | msn.com

Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?

November 21, 2023 | finance.yahoo.com

Organon To Present at the Piper Sandler 35th Annual Healthcare Conference

November 8, 2023 | morningstar.com

Organon & Co Ordinary Shares

November 7, 2023 | finance.yahoo.com

Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®

December 6, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 7, 2023 | seekingalpha.com

Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace

November 6, 2023 | baystreet.ca

Is This Healthcare Stock’s 8.7% Dividend Yield Safe?

November 5, 2023 | finance.yahoo.com

Organon & Co. (NYSE:OGN) Stock Goes Ex-Dividend In Just Four Days

November 3, 2023 | markets.businessinsider.com

Analyst Ratings for Organon

November 3, 2023 | msn.com

Goldman downgrades Organon following dismal Q3

November 3, 2023 | finance.yahoo.com

Organon & Co. (NYSE:OGN) Q3 2023 Earnings Call Transcript

November 3, 2023 | finance.yahoo.com

Organon & Co (OGN) Reports Q3 2023 Earnings: Revenue Drops 1% to $1.519 Billion

November 2, 2023 | seekingalpha.com

Organon stock plumbs all-time low on Q3 weakness in flagship women's health unit

November 2, 2023 | finance.yahoo.com

Organon Reports Results for the Third Quarter Ended September 30, 2023

November 1, 2023 | finance.yahoo.com

Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed

October 26, 2023 | finance.yahoo.com

Organon Canada Announces Availability of a High-Concentration, Citrate-Free Formulation of HADLIMA®, a Biosimilar to HUMIRA*

October 19, 2023 | finance.yahoo.com

Organon & Co (OGN) Declined in Q3

October 19, 2023 | finance.yahoo.com

Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023

October 4, 2023 | seekingalpha.com

Organon: The Federal Reserve Black Swan (Rating Upgrade)

September 27, 2023 | tmcnet.com

Organon Recognized on Fortune's 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice

September 27, 2023 | finance.yahoo.com

Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice

September 26, 2023 | finance.yahoo.com

On World Contraception Day, Organon Canada Declares Support for Universal Access to Contraception in Canada

September 14, 2023 | finance.yahoo.com

First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology

See More Headlines

Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/14 Dividend: 8/17/2023
Dividend Payable: 9/14/2023
Last Earnings: 11/02/2023
Ex-Dividend for 12/14 Dividend: 11/10/2023
Today: 12/06/2023
Dividend Payable: 12/14/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:OGN
CUSIP: N/A
CIK: 1821825
Web: www.organon.com
Phone: 551-430-6900
Fax: N/A
Employees: 10,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $23.33
High Stock Price Target: $33.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +110.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.29
Trailing P/E Ratio: 4.84
Forward P/E Ratio: 2.74
P/E Growth: 0.39
Net Income: $917 million
Net Margins: 9.51%
Pretax Margin: 11.06%
Return on Equity: -147.13%
Return on Assets: 9.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.63
Quick Ratio: 1.15

Sales & Book Value

Annual Sales: $6.15 billion
Price / Sales: 0.46
Cash Flow: $5.66 per share
Price / Cash Flow: 1.96
Book Value: ($3.51) per share
Price / Book: -3.16

Miscellaneous

Outstanding Shares: 255,606,000
Free Float: 252,615,000
Market Cap: $2.83 billion
Optionable: Not Optionable
Beta: 0.65

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Kevin Ali (Age 63)
CEO & Director
Comp: $3.96M
Mr. Matthew M. Walsh (Age 56)
Executive VP & CFO
Comp: $1.84M
Ms. Susanne Gabriele Fiedler (Age 55)
Executive VP & Chief Commercial Officer
Comp: $1.44M
Dr. Sandra Milligan J.D. (Age 59)
M.D., Executive VP and Head of Research & Development
Comp: $1.6M
Mr. Joseph T. Morrissey Jr. (Age 58)
Executive VP and Head of Manufacturing & Supply
Comp: $1.54M
Ms. Rachel A. Stahler (Age 47)
Executive VP & Chief Information Officer
Ms. Jennifer Halchak
Vice President of Investor Relations
Mr. Kirke Weaver (Age 50)
Executive VP, General Counsel & Corporate Secretary
Mr. Aaron Falcione (Age 52)
Executive VP & Chief Human Resources Officer
Mr. Vittorio Nisita (Age 55)
Executive VP & Head of Global Business Services

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

OGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OGN shares.
View OGN analyst ratings or view top-rated stocks.
What is Organon & Co.'s stock price target for 2024?: 5 Wall Street research analysts have issued twelve-month price targets for Organon & Co.'s stock. Their OGN share price targets range from $16.00 to $33.00. On average, they predict the company's share price to reach $23.33 in the next year. This suggests a possible upside of 110.4% from the stock's current price.
View analysts price targets for OGN or view top-rated stocks among Wall Street analysts.
How have OGN shares performed in 2023?: Organon & Co.'s stock was trading at $27.93 at the beginning of 2023. Since then, OGN shares have decreased by 60.3% and is now trading at $11.09.
View the best growth stocks for 2023 here.
Are investors shorting Organon & Co.?: Organon & Co. saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 14,620,000 shares, an increase of 36.3% from the October 31st total of 10,730,000 shares. Based on an average daily volume of 4,550,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 5.7% of the company's stock are short sold.
View Organon & Co.'s Short Interest.
When is Organon & Co.'s next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our OGN earnings forecast.
How were Organon & Co.'s earnings last quarter?: Organon & Co. (NYSE:OGN) announced its earnings results on Thursday, November, 2nd. The company reported $0.78 EPS for the quarter, missing analysts' consensus estimates of $1.04 by $0.26. The firm had revenue of $1.52 billion for the quarter, compared to analysts' expectations of $1.59 billion. Organon & Co. had a net margin of 9.51% and a negative trailing twelve-month return on equity of 147.13%.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?: Organon & Co. declared a quarterly dividend on Thursday, November 2nd. Stockholders of record on Monday, November 13th will be given a dividend of $0.28 per share on Thursday, December 14th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 10.10%. The ex-dividend date is Friday, November 10th.
Read our dividend analysis for OGN.
Is Organon & Co. a good dividend stock?: Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 9.74%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 48.91%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 26.92% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.
What ETFs hold Organon & Co.'s stock?: ETFs with the largest weight of Organon & Co. (NYSE:OGN) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Emerge EMPWR Sustainable Dividend Equity ETF (EMCA), Invesco S&P 500 High Dividend Low Volatility ETF (SPHD), First Trust Nasdaq Pharmaceuticals ETF (FTXH), VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE).
Who are Organon & Co.'s major shareholders?: Organon & Co.'s stock is owned by a variety of retail and institutional investors. Top institutional investors include Mawer Investment Management Ltd. (5.03%), Invesco Ltd. (4.01%), Massachusetts Financial Services Co. MA (3.63%), Lord Abbett & CO. LLC (1.97%), Sound Shore Management Inc CT (1.35%) and Morgan Stanley (1.19%).
View institutional ownership trends.
How do I buy shares of Organon & Co.?: Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:OGN) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial